Navigation Links
EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
Date:10/22/2007

ccessful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 or EPC 2407 will not be successful, that NP-1 or EPC 2407 will not receive regulatory approval or achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings which are available at http://www.sec.gov or at http://www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

* Azixa is a registered trademark of Myriad Genetics, Inc.

EPCT-GEN


'/>"/>
SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. EpiCept Accelerates Development of Phase I Clinical Study for Cancer
2. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
3. Researchers Present Ways To Reduce The Risk Of Dementia
4. Researchers Present Data Regarding The Efficiency Of Herbs
5. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
6. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
7. Drug Reactions First Present Themselves In The Mouth
8. Reminiscing Into The Past Makes You Dissatisfied With The Present
9. Living In The Past Indicates Dissatisfaction With Present
10. Movies Represent Coma In A Wrong Way
11. Onchocerciasis: Presentation And Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Los Angeles, California (PRWEB) , ... August 04, ... ... bearing drawer slides to Los Angeles commercial customers. Finding reliable hardware can ... create unfortunate liabilities. When putting an office together or designing a new ...
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide ... Power Products is expanding its reach in Texas. Effective July 1st of this ... North Texas generator division. With the North Texas acquisition, Worldwide Power Products ...
(Date:8/4/2015)... ... 2015 , ... Many men are confused about the safety of testosterone replacement ... as a voice of authority for men seeking accurate information about testosterone. , ... and expertise in the safe and effective treatment of low testosterone. In recent years, ...
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, ... Google” before calling a physician. In an effort to share more and better ... provider in Pennsylvania to publicly share patient satisfaction ratings and comments about its ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... mesothelioma patients whose cancer has come back: Retreatment may be a viable option. ... to read it now. , According to surgeons at the University of ...
Breaking Medicine News(10 mins):Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 2Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 3Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 4Health News:North Texas Acquisition Press Release 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2
... MYL ),today announced that in accordance with its 2.139 ... dividend of $15.53,per share (based on the annual dividend rate ... the time period from the date of,issuance to February 15, ... of record as of February 1, 2008., Mylan Inc. ...
... 30 OxySure(R) Systems, Inc.,announced today that the ... World,s,Best Technologies (WBT) in 2008. OxySure(R) has developed ... two inert, proprietary,powders. The company,s inclusion into the ... Generator, Model 615, which OxySure(R) launched,in late 2007. ...
... safe dosages of the isotope astatine-211 for patients ... to find that not only was the isotopes ... damaging sensitive healthy brain cells, but the patients ... much as five times or more cell-killing efficiency ...
... Low in Seasonal Illness affects sales of Cough ... Matrixx Initiatives, Inc.,(Nasdaq: MTXX ), an over-the-counter ... consumers with "Better Ways to Get,Better(R)," today announced ... nine months ended December 31, 2007. Third quarter ...
... Shares at the Annual Meeting of ... Stockholders on March 11, 2008), BEDFORD, Mass., ... technologies company specializing in,diagnostics imaging systems and interventional devices dedicated to ... Directors,has approved a two-for-one stock split, to be effected in the ...
... preserving Blue Cross,s nonprofit mission gives Michigan ... LANSING, Mich., Jan. 30 Creation of ... people rejected by,commercial insurers and HMOs because of ... the Michigan Senate Health Policy Committee,today. The Senate ...
Cached Medicine News:Health News:OxySure(R) Systems, Inc. Named to 2008 World's Best Technologies (WBT) List For its Unique, Safe and Easy to Use Portable Emergency Oxygen Generator, Which Provides Medical Oxygen Without the Need for Compressed Tanks 2Health News:Treatment capitalizes on unique qualities of radioisotope to prolong lives of brain tumor patients 2Health News:Treatment capitalizes on unique qualities of radioisotope to prolong lives of brain tumor patients 3Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 2Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 3Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 4Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 5Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 6Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 7Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 8Health News:Hologic Announces Two-For-One Stock Split 2Health News:Hologic Announces Two-For-One Stock Split 3Health News:Blue Cross Blue Shield of Michigan Says Guaranteed Access Provisions of Insurance Reform Bills Protect Michigan Consumers Twice-Over 2Health News:Blue Cross Blue Shield of Michigan Says Guaranteed Access Provisions of Insurance Reform Bills Protect Michigan Consumers Twice-Over 3
(Date:8/4/2015)... Transparency Market Research has published ... Market (BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, ... Volume, Share, Growth, Trends and Forecast 2014 - 2022 ... published by Transparency Market Research " Non-invasive Prenatal Testing ... Trends and Forecast 2014 - 2022 ", the global ...
(Date:8/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nl392k/alcohol ) has announced the ... (Household & Personal Care, Pharmaceutical, Oilfield, Agrochemicals, and Others) ... report to their offering. The market ... in 2014 and is projected to grow at a ... data mentioned in the report is based on the ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015  Mirati Therapeutics, ... focusing on genetic and epigenetic drivers of cancer, will be ... August 11, 2015 at 1:55 p.m. ET (10:55 a.m. PT) ... Baum , M.D., Ph.D., president and CEO of Mirati, will ... of the presentation will be accessible on the "Investors" page ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3
... YORK, Feb. 1, 2011 Reportlinker.com announces that a ... Pen Injectors ... of an increasing number of drugs in pre-filled disposable ... pens at the expense of other drug delivery methods ...
... Reportlinker.com announces that a new market research report ... Fludarabine - Comprehensive patent search ... with the industry benchmark in comprehensive patent information. ... professional patent search performed by our expert team, ...
Cached Medicine Technology:Reportlinker Adds Fludarabine - Comprehensive Patent Search 2Reportlinker Adds Fludarabine - Comprehensive Patent Search 3Reportlinker Adds Fludarabine - Comprehensive Patent Search 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: